Selected recent studies treating PMBCL
| Study . | Treatment . | Study type . | Patient characteristics . | Outcome . | |
|---|---|---|---|---|---|
| Chemotherapy . | RT± . | ||||
| Savage et al26 | CHOP/R-CHOP /MACOP- B/VACOP-B | Variable | Retrospective study, N = 153 | All IPI groups | At 5 y, PFS was 69%. Only MACOP-B/VACOP-B vs CHOP-like regimens were significantly different |
| Rieger et al24 | CHOP/R-CHOP | Variable, RT intended in 87% | Retrospective analysis, N = 87 | Confined to AA-IPI of 0-1 | At 3 y, EFS was 78% for R-CHOP and 52% for CHOP |
| Soumerai et al25 | R-CHOP | Yes, 77% of responding patients | Retrospective study, N = 63 | All IPI groups | At 5 y, PFS was 68% |
| Dunleavy et al28 | DA-EPOCH-R | No | Prospective study, N = 51 | All IPI groups | At 5 y, EFS was 93% |
| Martelli et al31 | R-MACOP-B, R-VACOP-B, R-CHOP | Yes | Prospective study, N = 125 | All IPI | Estimated 5 y PFS is 86% |
| Gleeson et al27 | R-CHOP-14 vs R- CHOP-21 | Yes | Retrospective analysis, N = 50 | Confined to stage I and II | 5 y PFS, 79.8% |
| Study . | Treatment . | Study type . | Patient characteristics . | Outcome . | |
|---|---|---|---|---|---|
| Chemotherapy . | RT± . | ||||
| Savage et al26 | CHOP/R-CHOP /MACOP- B/VACOP-B | Variable | Retrospective study, N = 153 | All IPI groups | At 5 y, PFS was 69%. Only MACOP-B/VACOP-B vs CHOP-like regimens were significantly different |
| Rieger et al24 | CHOP/R-CHOP | Variable, RT intended in 87% | Retrospective analysis, N = 87 | Confined to AA-IPI of 0-1 | At 3 y, EFS was 78% for R-CHOP and 52% for CHOP |
| Soumerai et al25 | R-CHOP | Yes, 77% of responding patients | Retrospective study, N = 63 | All IPI groups | At 5 y, PFS was 68% |
| Dunleavy et al28 | DA-EPOCH-R | No | Prospective study, N = 51 | All IPI groups | At 5 y, EFS was 93% |
| Martelli et al31 | R-MACOP-B, R-VACOP-B, R-CHOP | Yes | Prospective study, N = 125 | All IPI | Estimated 5 y PFS is 86% |
| Gleeson et al27 | R-CHOP-14 vs R- CHOP-21 | Yes | Retrospective analysis, N = 50 | Confined to stage I and II | 5 y PFS, 79.8% |
DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, plus rituximab; EFS, event-free survival; IPI, international prognostic index; OS, overall survival; R-MACOP-B, rituximab and methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; R-VACOP-B, rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin.